Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Neuroone Medical Technologies (NMTC) EBT Margin (2020 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed EBT Margin for 11 consecutive years, with 49.71% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin fell 10424.0% year-over-year to 49.71%, compared with a TTM value of 78.34% through Dec 2025, up 4667.0%, and an annual FY2025 reading of 39.63%, up 31711.0% over the prior year.
  • EBT Margin was 49.71% for Q4 2025 at Neuroone Medical Technologies, up from 59.08% in the prior quarter.
  • Across five years, EBT Margin topped out at 54.53% in Q4 2024 and bottomed at 13124.54% in Q1 2021.
  • Average EBT Margin over 5 years is 2945.3%, with a median of 653.18% recorded in 2023.
  • The sharpest move saw EBT Margin plummeted -557741bps in 2021, then skyrocketed 806028bps in 2023.
  • Year by year, EBT Margin stood at 8318.94% in 2021, then soared by 82bps to 1512.29% in 2022, then skyrocketed by 77bps to 342.14% in 2023, then soared by 116bps to 54.53% in 2024, then crashed by -191bps to 49.71% in 2025.
  • Business Quant data shows EBT Margin for NMTC at 49.71% in Q4 2025, 59.08% in Q3 2025, and 88.49% in Q2 2025.